Grifols SA ADR GIKLY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GIKLY is a good fit for your portfolio.
News
-
Johnson Fistel, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action Investigation - GRFS, GIKLY, GIFOF, GIFLF
-
ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action Investigation - GRFS, GIKLY, GIFOF, GIFLF
-
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action Investigation – GRFS, GIKLY, GIFOF, GIFLF
-
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action Investigation – GRFS, GIKLY, GIFOF, GIFLF
-
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action Investigation - GRFS, GIKLY, GIFOF, GIFLF
-
ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action Investigation – GRFS, GIKLY, GIFOF, GIFLF
-
ROSEN, A LEADING LAW FIRM, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action Investigation – GRFS, GIKLY, GIFOF, GIFLF
-
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action Investigation - GRFS, GIKLY, GIFOF, GIFLF
Trading Information
- Previous Close Price
- $4.47
- Day Range
- $4.52–4.52
- 52-Week Range
- $3.56–8.70
- Bid/Ask
- $4.30 / $4.62
- Market Cap
- $6.14 Bil
- Volume/Avg
- 195 / 5,323
Key Statistics
- Price/Earnings (Normalized)
- 35.14
- Price/Sales
- 0.86
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Mid Core
- Total Number of Employees
- 23,700
- Website
- https://www.grifols.com
Competitors
Valuation
Metric
|
GIKLY
|
CSL
|
PFE
|
---|---|---|---|
Price/Earnings (Normalized) | 35.14 | 29.71 | 15.08 |
Price/Book Value | 0.95 | 5.52 | 1.76 |
Price/Sales | 0.86 | 6.61 | 2.68 |
Price/Cash Flow | 9.83 | 34.48 | 14.40 |
Price/Earnings
GIKLY
CSL
PFE
Financial Strength
Metric
|
GIKLY
|
CSL
|
PFE
|
---|---|---|---|
Quick Ratio | 0.72 | 0.95 | 0.58 |
Current Ratio | 2.48 | 2.15 | 0.91 |
Interest Coverage | 1.28 | 7.21 | 0.74 |
Quick Ratio
GIKLY
CSL
PFE
Profitability
Metric
|
GIKLY
|
CSL
|
PFE
|
---|---|---|---|
Return on Assets (Normalized) | 1.17% | 8.11% | 4.98% |
Return on Equity (Normalized) | 4.22% | 18.17% | 10.90% |
Return on Invested Capital (Normalized) | 3.28% | 10.94% | 7.28% |
Return on Assets
GIKLY
CSL
PFE
Drug Manufacturers - General Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
LLY
| Eli Lilly and Co | Dyypyxty | Fjvfx | $739.7 Bil | |
JNJ
| Johnson & Johnson | Jmxsbwwp | Xmxs | $381.2 Bil | |
MRK
| Merck & Co Inc | Lfbkjmjg | Sylzb | $334.2 Bil | |
ABBV
| AbbVie Inc | Ttzsygz | Pzgq | $322.4 Bil | |
AZN
| AstraZeneca PLC ADR | Lqprsyff | Hwnn | $208.8 Bil | |
RHHBY
| Roche Holding AG ADR | Tdbckqqm | Nbxg | $203.8 Bil | |
NVS
| Novartis AG ADR | Bxmfbqpf | Hhp | $197.2 Bil | |
PFE
| Pfizer Inc | Hnhpptxjz | Xvz | $157.1 Bil | |
AMGN
| Amgen Inc | Zqkmxvnhn | Pknh | $152.4 Bil | |
SNY
| Sanofi SA ADR | Tmjpngxn | Qlkr | $122.8 Bil |